Study of zanubrutinib in Waldenström macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Waldenström macroglobulinemia (WM)
- Your blood test shows IgM (an antibody) is higher than 0.5 g/dL
- You are starting, already taking, or plan to take zanubrutinib for WM
- Your bone marrow test shows a specific MYD88 result (either MYD88 L265P or a non-L265P/MYD88WT type)
- There is no evidence that your WM has changed into a different, more aggressive cancer before starting zanubrutinib
- You do not have another non-Hodgkin lymphoma type, and you are not in another treatment trial while on zanubrutinib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
This study tests a combination of new and older drugs for Waldenström macroglobulinemia, a rare blood cancer. The drugs aim to block the cancer's growth signals and boost the body's immune attack. It is for people who have not yet had any treatment for this condition.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.